Novel Targets Podcast

Bringing to Life the Science around Innovative New Drugs, Gene and Cell Therapies

The promise of cancer immunotherapy and in particular checkpoint inhibitors that target the PD1 PDL1 signaling pathway is the topic of this episode.

We hear about the latest data presented at the 2015 annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Interviews with Dr Julie Brahmer (Johns Hopkins), Dr Leisha Emens (Johns Hopkins) and Dr Ira Mellman (Genentech) take us on a journey that highlights some of the challenges and opportunities.

Dr Leisha Emens Johns Hopkins

We also hear from Dr Suzanne Topalian (Johns Hopkins), Dr Antoni Ribas (UCLA) and Dr Pasi Jänne (Dana-Farber Cancer Institute).

Lung cancer is the leading cause of cancer death in the United States.

Dr Roy HerbstPersonalized Immunotherapy for Non-Small Cell Lung Cancer was the title of an outstanding presentation by Roy Herbst MD PhD, at last year’s annual meeting of the Society for Immunotherapy of Cancer (SITC).

Following his talk, Dr Herbst kindly shared his thoughts on lung cancer immunotherapy, and his experience of participating in clinical trials of checkpoint inhibitors that target the PD-1 (and it’s ligand PD-L1) cell signaling pathway.

This is the third prologue that “sets the scene” in cancer immunotherapy prior to the launch of the first episode of Novel Targets in a few weeks time.

Daniel Chen MD PhD Photo Credit: Genentech

Daniel Chen MD PhD, Photo Courtesy of Genentech

Cancer Immunotherapy is one of the topics we will be talking about a lot on the podcast. As we gear up to the first episode, we thought we would share a few stories that set the scene, what we are calling a prologue.

In this audio piece, you will hear Daniel Chen MD PhD (pictured right), Cancer Immunotherapy Head at Roche Genentech talk about how our immune system can be used to fight cancer.

The interview took place at the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).

One of the hottest topics in Cancer Research is using the body’s immune system to fight cancer. This report discusses the promise of Chimeric Antigen Receptor (CAR) T Cell Therapy.

It was previously broadcast on the Sound Medicine Radio Hour on March 22, 2015.

Dr Stephan Grupp presents data at ASH 2014 media briefing moderated by Dr Catherine Bollard

Dr Stephan Grupp presents data at ASH 2014 media briefing moderated by Dr Catherine Bollard

In it you will hear an interview with Dr Stephan Grupp (The Children’s Hospital of Philadelphia) who talks about the clinical trial results seen with CTL019, a new CAR T Cell therapy in development by Novartis & The University of Pennsylvania.